Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 492

1.

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study.

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators.

Lancet. 2020 Mar 20. pii: S0140-6736(20)30314-7. doi: 10.1016/S0140-6736(20)30314-7. [Epub ahead of print]

PMID:
32209449
2.

Molecular imaging in the era of precision medicine: paraganglioma as a template for understanding multiple levels of analysis.

Taieb D, Visvikis D, Hicks RJ, Pacak K.

J Nucl Med. 2020 Mar 13. pii: jnumed.119.239095. doi: 10.2967/jnumed.119.239095. [Epub ahead of print] No abstract available.

PMID:
32169918
3.

Abscopal Regressions of Lymphoma after Involved-Site Radiotherapy Confirmed by Positron Emission Tomography.

MacManus MP, Hofman MS, Hicks RJ, Campbell BA, Wirth A, Seymour JF, Haynes N, Burbury K.

Int J Radiat Oncol Biol Phys. 2020 Mar 6. pii: S0360-3016(20)30886-5. doi: 10.1016/j.ijrobp.2020.02.636. [Epub ahead of print]

PMID:
32151671
4.

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.

Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, Kong G, Akhurst T, Thang SP, Murphy DG, Williams S, Hofman MS.

Eur J Nucl Med Mol Imaging. 2020 Mar 5. doi: 10.1007/s00259-020-04723-z. [Epub ahead of print]

PMID:
32140802
5.

The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (18 F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors.

Lung MS, Hicks RJ, Pavlakis N, Link E, Jefford M, Thomson B, Wyld DK, Liauw W, Akhurst T, Kuru N, Michael M.

Asia Pac J Clin Oncol. 2020 Feb 7. doi: 10.1111/ajco.13307. [Epub ahead of print]

PMID:
32030887
6.

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma.

Kamel Hasan O, Ravi Kumar AS, Kong G, Oleinikov K, Ben-Haim S, Grozinsky-Glasberg S, Hicks RJ.

J Nucl Med. 2020 Jan 31. pii: jnumed.119.237990. doi: 10.2967/jnumed.119.237990. [Epub ahead of print]

PMID:
32005769
7.

Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Post-treatment SPECT/CT: A Novel Methodology to Generate Time- and Tissue-specific Dose Factors.

Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet JA.

J Nucl Med. 2019 Dec 5. pii: jnumed.119.233411. doi: 10.2967/jnumed.119.233411. [Epub ahead of print]

PMID:
31806772
8.

18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond.

Hicks RJ, Iravani A, Sandhu S.

PET Clin. 2020 Jan;15(1):11-22. doi: 10.1016/j.cpet.2019.08.007. Review.

PMID:
31735298
9.

Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Ravi Kumar A, Akhurst T, Pattison DA, Beaulieu A, Mooi J, Guo C, Kalff V, Murphy DG, Jackson P, Eu P, Scalzo M, Williams S, Hicks RJ, Hofman MS.

J Nucl Med. 2019 Nov 15. pii: jnumed.119.236414. doi: 10.2967/jnumed.119.236414. [Epub ahead of print]

PMID:
31732676
10.

Automated preparation of clinical grade [68Ga]Ga-DOTA-CP04, a cholecystokinin-2 receptor agonist, using iPHASE MultiSyn synthesis platform.

Haskali MB, Roselt PD, Binns D, Hetsron A, Poniger S, Hutton CA, Hicks RJ.

EJNMMI Radiopharm Chem. 2019 Aug 23;4(1):23. doi: 10.1186/s41181-019-0067-2.

11.

The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre.

Nan Tie E, Na LH, Hicks RJ, Spillane J, Speakman D, Henderson MA, Gyorki DE.

Ann Surg Oncol. 2019 Dec;26(13):4673-4680. doi: 10.1245/s10434-019-07965-w. Epub 2019 Oct 22.

PMID:
31641949
12.

Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.

Iravani A, Solomon B, Pattison DA, Jackson P, Ravi Kumar A, Kong G, Hofman MS, Akhurst T, Hicks RJ.

Thyroid. 2019 Nov;29(11):1634-1645. doi: 10.1089/thy.2019.0143.

PMID:
31637953
13.

Transrenal Ureteral Occlusion for Palliation of Refractory Urine Leaks Using Vascular Plugs and Liquid Ethylene Vinyl Alcohol.

Jalaeian H, Hicks RJ, Hartnell GG, Janne d'Othée B.

J Vasc Interv Radiol. 2019 Dec;30(12):1994-2001. doi: 10.1016/j.jvir.2019.04.029. Epub 2019 Sep 14.

PMID:
31530488
14.

Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals.

Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O'Toole D, Ruszniewski P, Wiedenmann B, Hollander R; International Neuroendocrine Cancer Alliance (INCA).

Int J Cancer. 2020 Mar 1;146(5):1316-1323. doi: 10.1002/ijc.32678. Epub 2019 Oct 25.

15.

Peptide Receptor Radiotherapy: Current Approaches and Future Directions.

Kong G, Hicks RJ.

Curr Treat Options Oncol. 2019 Aug 29;20(10):77. doi: 10.1007/s11864-019-0677-7. Review.

PMID:
31468210
16.

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K.

Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.

PMID:
31440799
17.

A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention.

Zia NA, Cullinane C, Van Zuylekom JK, Waldeck K, McInnes LE, Buncic G, Haskali MB, Roselt PD, Hicks RJ, Donnelly PS.

Angew Chem Int Ed Engl. 2019 Oct 14;58(42):14991-14994. doi: 10.1002/anie.201908964. Epub 2019 Sep 5.

PMID:
31437347
18.

How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology.

Lasocki A, Hicks RJ.

Cancer Imaging. 2019 Aug 19;19(1):57. doi: 10.1186/s40644-019-0241-5. Review.

19.

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.

Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG, Williams SG, Hicks RJ, Hofman MS.

Eur Urol Oncol. 2019 Nov;2(6):670-676. doi: 10.1016/j.euo.2018.11.007. Epub 2018 Dec 13.

PMID:
31412006
20.

Early Outcomes of Surgery for Carcinoid Heart Disease.

Yong MS, Kong G, Ludhani P, Michael M, Morgan J, Hofman MS, Hicks RJ, Larobina M.

Heart Lung Circ. 2019 Jun 12. pii: S1443-9506(19)30606-7. doi: 10.1016/j.hlc.2019.05.183. [Epub ahead of print]

PMID:
31383543
21.

Characterizing high-grade serous papillary carcinoma of tunica vaginalis.

Qu LG, Teh J, Mitchell C, Gyorki DE, Hicks RJ, Murphy DG.

Urol Case Rep. 2019 Jun 21;26:100949. doi: 10.1016/j.eucr.2019.100949. eCollection 2019 Sep.

22.

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, Virgolini IJ, Fanti S, Balogova S, Pandit-Taskar N, Pacak K.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137. doi: 10.1007/s00259-019-04398-1. Epub 2019 Jun 29.

PMID:
31254038
23.

Molecular Imaging of Recurrent and Metastatic Prostate Cancer.

Ware RE, Williams S, Hicks RJ.

Semin Nucl Med. 2019 Jul;49(4):280-293. doi: 10.1053/j.semnuclmed.2019.02.005. Epub 2019 Mar 21. Review.

PMID:
31227051
24.

PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.

Iravani A, Turgeon GA, Akhurst T, Callahan JW, Bressel M, Everitt SJ, Siva S, Hofman MS, Hicks RJ, Ball DL, Mac Manus MP.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1869-1877. doi: 10.1007/s00259-019-04388-3. Epub 2019 Jun 12.

PMID:
31190177
25.

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.

Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T, Tiong IS, Blombery P, Hofman MS, Westerman D, Hicks RJ, Kong G.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910. doi: 10.1007/s00259-019-04389-2. Epub 2019 Jun 11.

PMID:
31187162
26.

The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!

Hung TJ, McLean L, Mitchell C, Pascoe C, Lawrentschuk N, Murphy DG, Iravani A, Singh D, Hofman MS, Zidan L, Akhurst T, Lewin J, Hicks RJ.

Cancer Imaging. 2019 May 29;19(1):28. doi: 10.1186/s40644-019-0217-5.

27.

Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.

Murphy DG, Hofman MS, Azad A, Violet J, Hicks RJ, Lawrentschuk N.

BJU Int. 2019 May 24. doi: 10.1111/bju.14814. [Epub ahead of print] No abstract available.

PMID:
31127664
28.

Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution.

Ferreira G, Iravani A, Hofman MS, Hicks RJ.

Cancer Imaging. 2019 May 15;19(1):23. doi: 10.1186/s40644-019-0211-y.

29.

Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria.

Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson KSJ, Gückel B, Jačan A, Haslacher H, Hicks RJ, Kenner L, Langanke M, Mitterhauser M, Pichler BJ, Salih HR, Schibli R, Schulz S, Simecek J, Simon J, Soares MO, Stelzl U, Wadsak W, Zatloukal K, Zeitlinger M, Hacker M.

Mol Imaging Biol. 2020 Feb;22(1):47-65. doi: 10.1007/s11307-019-01361-2.

PMID:
31049831
30.

Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study.

Le Roux PY, Iravani A, Callahan J, Burbury K, Eu P, Steinfort DP, Lau E, Woon B, Salaun PY, Hicks RJ, Hofman MS.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1596-1604. doi: 10.1007/s00259-019-04338-z. Epub 2019 May 1.

PMID:
31044265
31.

The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma.

Kong G, Schenberg T, Yates CJ, Trainer A, Sachithanandan N, Iravani A, Ravi Kumar A, Hofman MS, Akhurst T, Michael M, Hicks RJ.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):5091-5099. doi: 10.1210/jc.2019-00018.

PMID:
30977831
32.

FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia.

Douglas AP, Thursky KA, Worth LJ, Harrison SJ, Hicks RJ, Slavin MA.

Leuk Lymphoma. 2019 Oct;60(10):2471-2476. doi: 10.1080/10428194.2019.1590571. Epub 2019 Apr 5.

PMID:
30947578
33.

CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience.

Sahu A, Jefford M, Lai-Kwon J, Thai A, Hicks RJ, Michael M.

J Oncol. 2019 Feb 20;2019:9032753. doi: 10.1155/2019/9032753. eCollection 2019.

34.

The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy.

Metser U, Chua S, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsawy A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott AM, Tunariu N, Sidhu H, Emmett L.

J Nucl Med. 2019 Sep;60(9):1253-1258. doi: 10.2967/jnumed.118.225185. Epub 2019 Mar 22.

PMID:
30902875
35.

Modification of Biodistribution and Brain Uptake of Copper Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine Functional Groups.

Paterson BM, Cullinane C, Crouch PJ, White AR, Barnham KJ, Roselt PD, Noonan W, Binns D, Hicks RJ, Donnelly PS.

Inorg Chem. 2019 Apr 1;58(7):4540-4552. doi: 10.1021/acs.inorgchem.9b00117. Epub 2019 Mar 14.

PMID:
30869878
36.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ.

Ann Oncol. 2019 May 1;30(5):804-814. doi: 10.1093/annonc/mdz048.

37.

Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT.

Pattison DA, MacFarlane LL, Callahan J, Kane EL, Akhurst T, Hicks RJ.

EJNMMI Res. 2019 Feb 8;9(1):15. doi: 10.1186/s13550-019-0480-2.

38.

2020 vision or myopia? A personal perspective on the future of cancer imaging and an introduction to the sequels to the "How I Read Series".

Hicks RJ.

Cancer Imaging. 2019 Feb 6;19(1):7. doi: 10.1186/s40644-019-0194-8. No abstract available.

39.

Metabolic patterns and seizure outcomes following anterior temporal lobectomy.

Cahill V, Sinclair B, Malpas CB, McIntosh AM, Chen Z, Vivash LE, O'Shea MF, Wilson SJ, Desmond PM, Berlangieri SU, Hicks RJ, Rowe CC, Morokoff AP, King JA, Fabinyi GC, Kaye AH, Kwan P, Berkovic SF, O'Brien TJ.

Ann Neurol. 2019 Feb;85(2):241-250. doi: 10.1002/ana.25405. Epub 2019 Jan 17.

PMID:
30609109
40.

PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA.

Le Roux PY, Hicks RJ, Siva S, Hofman MS.

Semin Nucl Med. 2019 Jan;49(1):71-81. doi: 10.1053/j.semnuclmed.2018.10.013. Epub 2018 Nov 17. Review.

PMID:
30545520
41.

Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.

Reynolds HM, Williams S, Jackson P, Mitchell C, Hofman MS, Hicks RJ, Murphy DG, Haworth A.

BJU Int. 2019 Jun;123(6):1020-1030. doi: 10.1111/bju.14648. Epub 2019 Jan 28.

PMID:
30536698
42.

Consensus on molecular imaging and theranostics in prostate cancer.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG.

Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1.

PMID:
30507436
43.

Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes.

Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond G, Chua S, Ho B, Johnston E, Pouliot F, Scott AM.

J Nucl Med. 2019 Jun;60(6):794-800. doi: 10.2967/jnumed.118.220103. Epub 2018 Nov 15.

44.

64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy.

Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, Akhurst TA, Drummond E, Roselt P, Callahan J, Price R, Jeffery CM, Hong E, Noonan W, Herschtal A, Hicks LJ, Hedt A, Harris M, Paterson BM, Donnelly PS.

J Nucl Med. 2019 Jun;60(6):777-785. doi: 10.2967/jnumed.118.217745. Epub 2018 Nov 15.

45.

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S.

Eur J Cancer. 2018 Dec;105:88-102. doi: 10.1016/j.ejca.2018.09.027. Epub 2018 Nov 13.

PMID:
30439628
46.

An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement.

Freudenberg LS, Hicks RJ, Beyer T.

J Nucl Med. 2019 Apr;60(4):480-485. doi: 10.2967/jnumed.118.218073. Epub 2018 Nov 2.

PMID:
30389815
47.

Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).

Kong G, Grozinsky-Glasberg S, Hofman MS, Akhurst T, Meirovitz A, Maimon O, Krausz Y, Godefroy J, Michael M, Gross DJ, Hicks RJ.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):718-727. doi: 10.1007/s00259-018-4196-8. Epub 2018 Oct 20.

PMID:
30343432
48.

FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.

Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250. doi: 10.1007/s00259-018-4171-4. Epub 2018 Oct 5. Review.

49.

Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.

Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS.

J Nucl Med. 2019 Apr;60(4):517-523. doi: 10.2967/jnumed.118.219352. Epub 2018 Oct 5.

PMID:
30291192
50.

A pilot study of cardiopulmonary exercise testing and cardiac stress positron emission tomography before major non-cardiac surgery.

Ferguson MT, Hofman MS, Ismail H, Melville A, Yap KSK, Hicks RJ, Wright S, Riedel B.

Anaesthesia. 2018 Dec;73(12):1524-1530. doi: 10.1111/anae.14447. Epub 2018 Oct 3.

Supplemental Content

Loading ...
Support Center